U-RHHBY

Q:RHHBY - ROCHE HOLDINGS AG SPN ADR EACH REP 0.125 GENUS - http://roche.com

14:58:32 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
RHHBY - Q	not subscribed					30.45	-0.79	-2.5	2,653.8	80,391	4,012	30.39 30.57 30.15	40.48 29.95	14:38:01	Apr 18	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
OTC Markets Indicators -- Primary Market: OTC Markets -- Tier: OTCQX International Premier -- Status: Active

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Portfolio

Recent Trades - Last 10 of 4012

More trades...

Time ET	Ex	Price	Change	Volume
14:38:02	Q	30.45	-0.79	203
14:38:02	Q	30.45	-0.79	100
14:38:01	Q	30.445	-0.795	22
14:37:56	Q	30.45	-0.79	408
14:37:56	Q	30.45	-0.79	293
14:37:56	Q	30.45	-0.79	287
14:37:56	Q	30.45	-0.79	291
14:37:56	Q	30.45	-0.79	203
14:37:56	Q	30.45	-0.79	97
14:37:56	Q	30.45	-0.79	3

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2024-04-18 16:35	U:RHHBY	News Release200	FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
2024-04-17 02:06	U:RHHBY	News Release200	Genentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
2024-04-15 01:10	U:RHHBY	News Release200	Genentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
2024-04-10 01:00	U:RHHBY	News Release200	Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

Date ET

Symbol

Type

Headline

2024-04-18 16:35

U:RHHBY

News Release

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

2024-04-17 02:06

U:RHHBY

News Release

Genentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS